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Infiltrating macrophages and T cells are instrumental in autoimmune
kidney destruction of MRL-Faslpr mice. We report that the b-chemokine
RANTES, a chemoattractant for macrophages and T cells, is up-regulated
in the MRL-Faslpr kidney prior to injury, but not normal kidneys (MRL-
11, C3H-11) and increases with progressive injury. Furthermore, we
establish an association between RANTES expression in the kidney and
renal damage using a gene transfer approach. Tubular epithelial cells
genetically modified to secrete RANTES infused under the renal capsule
incites interstitial nephritis in MRL-Faslpr, but not MRL-11 or C3H-11
mice. RANTES recruits predominantly macrophages (Mø) and CD41 and
CD81 T cells. In contrast, gene transfer of CSF-1, another molecule
up-regulated simultaneously with RANTES in MRL-Faslpr kidneys, pro-
motes the influx of Mø, CD41 T cells and the unique double-negative
(DN) T cells (CD42,CD82), which are prominent in diseased MRL-Faslpr
kidneys. Thus, RANTES and CSF-1 recruit distinct T cell populations into
the MRL-Faslpr kidney. In addition, delivery of RANTES and CSF-1 into
the kidney of MRL-Faslpr mice causes an additive increase in pathology.
We suggest that the complementary recruitment of T cell populations by
RANTES (CD4, CD8) and CSF-1 (CD4, DN) promotes autoimmune
nephritis in MRL-Faslpr mice.
The MRL-Faslpr mouse is a particularly appealing model of
human systemic lupus erythematosus, since renal disease is rapid,
predictable and regulated by a single gene mutation [1]. Nephritis
in MRL-Faslpr mice is complex, with glomerular, perivascular, and
interstitial components, and the rapid disease progression is fatal
(50% mortality at 6 months of age) [2]. By contrast, renal disease
in congenic MRL-11 mice lacking the Faslpr mutation is indo-
lent, and is not evident until the second year of life. Thus, the
Faslpr mutation accelerates renal disease in the predisposed
autoimmune MRL strain [2]. Fas mediates apoptosis of autore-
active T cells in the periphery. Mutation of this gene (Faslpr)
results in the accumulation of a unique subset of “double nega-
tive” (DN) T cells (CD42, CD82, B2201) in MRL-Faslpr mice [1].
Macrophage (Mø) and T cell infiltration is a prominent compo-
nent of the renal pathology in MRL-Faslpr mice [3, 4]. Multiple T
cell subsets are present in renal lesions; equal numbers of CD41
and DN T cells accumulate in perivascular, glomerular, and
interstitial lesions, while fewer CD81 T cells accumulate, predom-
inantly in the interstitium. However, the molecules responsible for
recruiting and activating these inflammatory cells in the kidney
have not been clearly defined.
MRL-Faslpr mice have multiple cytokine abnormalities prior to
the onset of autoimmune injury that are thought to promote
disease progression. We and others have reported up-regulation
of colony stimulating factor-1 (CSF-1), tumor necrosis factor-a
(TNF-a), interleukin (IL)-1b, transforming growth factor-B
(TGF-b), and IL-6 in MRL-Faslpr mice [3–8]. To define the
importance of a single cytokine in the pathogenesis of kidney
disease, ideally the cytokine should be expressed in a selected cell
type in a specific location in the mature kidney. Gene transfer
strategies that tailor cytokine expression in selected sites in the
kidney have been limited by the lack of tissue specific promoters,
and short-lived and variable expression of the transferred mole-
cules [9–11]. To overcome these obtacles, we devised an ex vivo
gene transfer system using retrovirally modified tubular epithelial
cells (TEC) as a carrier cell to deliver cytokines into the kidney
[12]. Syngeneic tubular epithelial cells, genetically engineered ex
vivo to express a cytokine, are infused under the renal capsule,
where they remain localized and provide stable, sustained delivery
of cytokine into the kidney. Using this gene transfer approach, we
established that CSF-1, but not TNF-a or IL-6, elicits renal injury
in MRL-Faslpr mice [12–15 ]. In spontaneous disease, CSF-1 is
up-regulated in MRL-Faslpr, but not congenic MRL-11 mice,
normal strains or other strains with the Faslpr mutation, well in
advance of renal disease, and increases in proportion to the
severity of kidney damage [3, 16]. Our finding that introduction of
CSF-1 initiates renal damage in MRL-Faslpr mice is supported by
compelling evidence from experiments in which single nephritic
MRL-Faslpr kidneys transplanted into MRL-11 mice resulted in
a loss of CSF-1 expression, the disappearance of Mø and the
reversal of renal lesions [17]. Taken together, we conclude that
CSF-1 is responsible for attracting and fostering Mø and T cells in
the MRL-Faslpr kidney. This prompted us to determine whether
other molecules in addition to CSF-1 contributed to the accumu-
lation of Mø and T cells in MRL-Faslpr kidneys.
The migration of leukocytes into an inflammatory site requires
the generation of a chemotactic gradient by cells of the extravas-
cular compartment. The b-chemokine, RANTES (Regulated
upon Activation, Normal T cell Expressed and Eecreted), is
chemotactic for monocytes and T cells, and induces cellular
activation of these leukocytes [18–20]. RANTES is expressed by
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renal mesangial and tubular epithelial cells (TEC) [21–23], and by
T lymphocytes in vitro [24]. In addition, RANTES can promote
the adhesion of invading leukocytes to matrix components of
glomeruli [25]. Thus, the release of RANTES by intrinsic renal
cells may initiate the influx of leukocytes into the kidney and
promote autoimmune inflammatory renal injury. Therefore, we
tested the hypothesis that RANTES initiates Mø and T cell
recruitment into the MRL-Faslpr kidney. We now report that
RANTES is expressed in the kidney of MRL-Faslpr mice prior to
the onset of autoimmune renal injury. Using a retroviral gene
transfer strategy, the consequence of RANTES expression in the
recruitment and propagation of inflammatory cells was evaluated
in the MRL-Faslpr kidney. RANTES fostered the accumulation of
a distinct subset of T cells (CD41 .CD81 ..DN), and initiates
renal damage. By contrast, CSF-1, which is simultaneously up-
regulated, promoted the influx of DN and CD41 T cells, but few
CD81 T cells. Thus, we propose that RANTES and CSF-1 are
complementary in promoting autoimmune nephritis by their
recruitment of Mø and different T cell subsets into the MRL-
Faslpr kidney.
METHODS
Mice
MRL/MpJ-11 (MRL-11), MRL/MpJ-Faslpr/Faslpr (MRL-
Faslpr) and C3H-HeJ (C3H-11) mice were purchased from the
Jackson Laboratories (Bar Harbor, ME, USA) or bred in our
pathogen-free animal facility.
Retrovirus-mediated cytokine gene transfer into cultured
tubular epithelial cells
Tubular epithelial cells (TEC) derived from MRL-Faslpr,
MRL-11 and C3H-11 mice one to two months of age were
isolated as previously described [26]. Briefly, kidneys were re-
moved and renal cortices were minced, dispersed in collagenase
solution, and passed through a series of steel sieves (250, 150, 75
and 38 mm). Cells were collected, resuspended in modified K1
medium (50% DMEM, 50% Ham’s F12, 10% FCS, 100 U/ml each
of penicillin and streptomycin, 10 mM HEPES), and incubated for
one hour at 37°C. Non-adherent cells were transfered to Primaria
tissue culture plates (Falcon Labware) and grown to confluence.
Prior to retroviral infection, TEC were trypsinized and plated at
1 3 106 cells/10-cm plate for 18 hours.
CRIP packaging cell lines producing helper-free recombinant
retroviruses carrying cytokine genes were generated as previously
described [27]. Briefly, the DNA sequence encoding RANTES
was subcloned into the MoMuLV-based MFG vector containing
the long terminal repeat viral promoter and the c sequence
necessary for viral RNA packaging. The MFG vector carrying the
RANTES gene was transfected into a 3T3 packaging cell line
(CRIP) containing the proviral sequences necessary for encapsi-
dation of the recombinant viral RNA. The resulting virus-produc-
ing cell line elaborates recombinant retroviruses that stably trans-
fer the recombinant viral genome containing the RANTES gene
upon infection of a suitable host cell. Producer cells were grown in
DMEM complete medium (10% FCS, 100 U/ml each of penicillin
and streptomycin, 10 mM HEPES) to subconfluence (5 3 106
cells/10 cm dish), replenished with 8 ml of fresh medium and
incubated for 18 hours. The virus-containing cell culture super-
natant was harvested, filtered through a 0.45 mm membrane, and
applied to TEC cultures as previously described [12]. Following
retroviral infection, TEC were replenished with K1 medium, and
grown to confluence. RANTES gene transfer into TEC was
verified and quantitated by Northern analysis as described above.
The retroviral transfer of the CSF-1 and TNF-a gene into TEC
has been previously established in our laboratory and character-
ized in detail [12–14]. Genetically modified cytokine producing
TEC retain the ability to produce cytokine in vitro for at least 10
months, and upon implantation, persist under the renal capsule
for up to 28 days [12]. Prior to infusion under the renal capsule,
production of CSF-1 by transduced TEC was verified by bone
marrow proliferation assay, and production of TNF-a was verified
by ELISA assay (Endogen, Woburn, MA, USA) as previously
described [12, 14]. In this manuscript, we abbreviate TEC trans-
duced with the RANTES, CSF-1, and TNF-a genes as RANTES-
TEC, CSF-1-TEC, or TNF-TEC, respectively.
Northern analysis
RNA was extracted and Northern blot analyses were performed
as previously described [3]. Total RNA was isolated from cultured
TEC or dissected renal cortices using RNAzol B (Tel-Test Inc.,
Friendswood, TX, USA), which is a modification of the gua-
nidium thiocyanate-phenol-chloroform method [28]. Total RNA
(20 mg) was electrophoresed through a 1% agarose-formaldehyde
gel, blotted to nylon membrane and hybridized in 50% formamide
with 32P-labeled nick-translated probes at 42°C. Hybridized mem-
branes were washed in 2 3 SSC, 0.1% SDS at room temperature
and 0.2 3 SSC, 0.1% SDS at 60°C. Autoradiography was per-
formed using a PhosphoImager (Molecular Dynamics Corp.,
Sunnyvale, CA, USA). The RANTES probe was kindly provided
by Dr. E. Neilson (University of Pennsylvania Medical Center,
PA, USA) and consisted of a 450 kb fragment of the PBS KS
plasmid containing the cDNA. Blots were reprobed with b-actin
(Pst-1 fragment of pBA-1) as an internal control for quantity and
integrity of RNA. Densitometry analysis was performed to quan-
titate mRNA expression.
Immunocytochemical evaluation of tubular epithelial cells
TEC were cultured in chamber slides (2 3 104 cells/well)
overnight and treated with 5 mM monensin (Boehringer Mann-
heim) for three hours prior to staining. TEC were fixed in acetone
and incubated for 30 minutes with 2.5% goat serum, followed by
goat anti-human RANTES Ab (20 mg/ml; 1 hr; R & D Systems),
which is weakly cross-reactive for mouse RANTES. Cells were
rinsed three times with phosphate buffered saline (PBS) and
immunoreactivity was visualized by incubating with rabbit anti-
goat IgG-FITC conjugated Ab for one hour.
Western analysis
Cell culture supernatants (48 hr) were collected from 5 3 106
MRL-Faslpr and C3H-11 RANTES-TEC or uninfected TEC and
concentrated fourfold using centricon concentrators-3 (Amicon,
Beverly, MA, USA). Samples were heat denatured in the presence
of Laemmli sample buffer containing 5% 2-mercaptoethanol and
electrophoresed on a 15% linear gradient SDS-PAGE gel. Pro-
teins were transfered to polyvinylidene difluoride membranes
(Millipore, Bedford, MA, USA) in the presence of Towbin
transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH
8.3) using a wet electrophoretic transfer apparatus. Membranes
were blocked in TBS-T (Tris buffered saline/0.1% Tween-20)
Moore et al: RANTES accelerates autoimmune renal damage1632
containing 5% (wt/vol) non-fat dry milk for one hour, and then
incubated in fresh buffer containing rabbit anti-murine RANTES
Ab (1:2000) for one hour. Membranes were washed in TBS-T and
incubated with peroxidase conjugated anti-rabbit Ab (1:20000) in
TBST-T/5% dry milk. Immunoreactive proteins were visualized
using the enhanced chemiluminescence detection system (Dupont
NEN, Boston, MA, USA) and exposed to X-ray film.
Infusion of tubular epithelial cell under the renal capsule
Using our gene transfer strategy, we have previously established
that delivery of CSF-1 under the renal capsule incites an accumu-
lation of Mø and T cells in the kidney of MRL-Faslpr mice six
weeks of age or older, but not in younger mice [12]. Therefore, we
delivered RANTES into the kidney of mice that were 6 to 8 weeks
of age at the time of TEC implantation to study the impact of
RANTES overexpression on the kidney. We placed RANTES-
TEC, CSF-1-TEC, or uninfected TEC under the renal capsule of
syngeneic MRL-Faslpr, MRL-11 or C3H-11 mice as previously
described [12]. We anesthetized mice with sodium pentobarbital
and ether, and exposed the left kidney through a flank incision. A
cell suspension of 1 3 106 TEC in 50 ml of HBSS was infused
under the renal capsule, and the peritoneum and skin were
sutured. Mice were sacrificed 7, 14 or 28 days post-implantation
(post-Ix) and the implanted kidney and control contralateral
kidney were removed for histological evaluation.
To establish the combined effect of CSF-1 and RANTES on the
MRL-Faslpr kidney, we placed equal numbers of (1 3 106)
RANTES-TEC and CSF-1-TEC, or RANTES-TEC and unin-
fected TEC, or CSF-1-TEC and uninfected TEC under the renal
capsule of MRL-Faslpr mice as described above. Mice were
sacrificed at 28 days post-Ix and the implanted kidney and control
contralateral kidney were removed for histological evaluation.
Histological evaluation
Kidneys were halved and fixed in 10% phosphate-buffered
formalin for paraffin-embedded sections or snap-frozen in OCT
compound (Miles, Naperville, IL, USA). Paraffin-embedded tis-
sue sections were stained by the hematoxylin and eosin (H & E)
method and evaluated by light microscopy. Sequential frozen
sections (6 m) were taken every 250 m and stained with toluidine
blue to identify the area of largest cell accumulation in the implant
site, as previously described [12–14]. The mean subcapsular cell
accumulation in TEC implanted kidneys was evaluated by count-
ing the cell layers in the area of accumulation under the capsule.
Intrarenal lesions emanating from the subcapsular implant were
scored according to the depth of infiltration into the kidney: 0 5
none, 1 5 cortex, 2 5 inner cortex, 3 5 medulla. To evaluate T
cell and Mø accumulation in the kidney, we stained sequentially
sectioned tissue specimens by the immunoperoxidase technique
using purified rat anti-mouse Abs to F4/80 Ag (Mø), CD4 (T cell),
CD8 (T cell), and CD21/35 (B cell) and the B220 determinant (B
cell, DN T cell) (Pharmingen, San Diego, CA, USA) as previously
described [12–15]. We identified the unique DN T cells
(CD42,CD82, CD21/352, B2201) by examining sequential sec-
tions. In brief, endogenous peroxidase (0.6% H2O2, 0.2% sodium
azide; 10 min), and avidin and biotin (Avidin/Biotin blocking kit;
Vector Laboratories, Burlingame, CA, USA) were blocked prior
to incubating the tissue sections with primary Abs (5 mg/ml, 2 hr).
Sections were washed in TBS/BSA 0.1% and incubated with
biotinylated goat anti-rat IgG (mouse adsorbed) for one hour. We
exposed the tissue sections to avidin-peroxidase complex (Vector
Elite Kit; Vector Laboratories) for one hour, followed by 3-39-
diamino-benzidine (0.5 mg/ml in TBS containing 0.02% H2O2) for
a chromogenic reaction and counterstained with methyl green/
alcian blue. Specificity controls included replacement of primary
Ab with normal rat IgG. Immunohistochemical staining was
analyzed by counting the number of F4/801, CD41, CD81, or
CD21/352B2201 in more than six random fields (340) in the
induced lesion. These analyses were performed independently by
two investigators in a blinded fashion. Statistical analyses were
performed using the Mann-Whitney m test.
RESULTS
RANTES mRNA is expressed in MRL-Faslprkidneys
By Northern analysis, we determined that RANTES is ex-
pressed in the MRL-Faslpr kidney prior to overt renal injury, and
increases with advancing renal pathology (Fig. 1). RANTES
mRNA is expressed in MRL-Faslpr kidney cortex as early as two
months of age, and is highly up-regulated in MRL-Faslpr kidney
cortex at six months of age during fulminant renal disease. In
contrast, RANTES mRNA is absent in mice with normal kidneys,
including congenic MRL-11 (2 and 10 months of age) and
C3H-11 (5 months of age) strains. This pattern of RANTES
up-regulation in the MRL-Faslpr kidney parallels that previously
described for CSF-1 and TNF-a [3–5].
RANTES incites renal damage in autoimmune MRL-Faslpr
mice
Primary renal TEC were retrovirally transduced with the
RANTES gene sequence, to create a cellular vehicle for the
constitutive delivery of RANTES into the kidney. We verified that
the transduced TEC expressed RANTES in culture (Fig. 2). Both
MRL-Faslpr and C3H-11 TEC constitutively express high levels
of RANTES mRNA after retroviral gene transfer (Fig. 2A). By
contrast, uninfected MRL-Faslpr and C3H-11 TEC do not
Fig. 1. RANTES mRNA is expressed in MRL-Faslpr kidneys. Total RNA
was extracted from kidney cortex of MRL-Faslpr mice 2, 4, and 6 months
of age (lanes 1, 2, 3), congenic MRL-11 mice 2 and 10 months of age
(lanes 4, 5), and normal C3H-11 mice five months of age (lane 6). A total
of 20 mg of RNA was electrophoresed, blotted and hybridized with a DNA
probe for mouse RANTES and reprobed with b-actin. Each time point
reflects the pooled kidney cortex RNA from 3 mice. Results are repre-
sentative of 2 separate experiments.
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Fig. 2. Primary culture tubular epithelial cells (TEC) retrovirally transduced with the RANTES gene sequence constitutively express RANTES. (A)
Northern analysis demonstrating expression of RANTES mRNA by transduced RANTES-TEC but not uninfected TEC. Total RNA (10 mg) from
uninfected (lanes 1, 2) or RANTES-TEC (lanes 3, 4) derived from MRL-Faslpr or normal C3H-11 mice was hybridized with a DNA probe for mouse
RANTES, and reprobed with b-actin. (B) Immunohistochemical staining documenting the expression of RANTES by transduced RANTES-TEC, but
not uninfected TEC. RANTES-TEC (panel I) and uninfected TEC (panel II) from MRL-Faslpr (top) or C3H-11 (bottom) were incubated with goat
anti-human RANTES-Ab and immunoreactivity was visualized with a rabbit anti-goat IgG-FITC conjugated Ab (magnification 3400). (C) Western
analysis verifying secretion of RANTES by transduced RANTES-TEC, but not uninfected TEC. Cell culture supernatants from MRL-Faslpr and
C3H-11 RANTES-TEC or uninfected TEC were subjected to Western analysis and RANTES protein was detected using a rabbit anti-murine
RANTES Ab as described in the Methods section.
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express endogenous RANTES mRNA. RANTES protein expres-
sion by transduced TEC was confirmed by staining for the
presence of RANTES by immunohistochemistry (Fig. 2B).
RANTES was detected in the cytoplasm of . 90% of MRL-Faslpr
and C3H-11 RANTES-TEC, but not in uninfected TEC of
either strain. Furthermore, MRL-Faslpr and C3H-11 RANTES-
TEC secreted similar levels of RANTES into the culture media as
determined by Western analysis (Fig. 2C). These data confirm
that the RANTES gene was successfully integrated into the TEC
genome resulting in constitutive expression, and that uninfected
TEC do not express RANTES.
To determine whether RANTES expression in the kidney
incites renal damage, RANTES-TEC was infused under the renal
capsule of syngeneic MRL-Faslpr, MRL-11, or C3H-11 mice at
two months of age, and examined kidney pathology at 7, 14 and 28
days post-implantation (Ix). RANTES incites an accumulation of
mononuclear cells under the renal capsule in MRL-Faslpr mice,
which infiltrate into the cortex forming a lesion, as early as seven
days post-Ix (Fig. 3). By 14 days post-Ix, these invading cells
expand into the inner cortex of the MRL-Faslpr kidney. In
contrast, RANTES-TEC only induced a cortical lesion in one of
four congenic MRL-11 mice at this time point. By 28 days
post-Ix, a massive accumulation of mononuclear cells is apparent
under the renal capsule in MRL-Faslpr mice, which infiltrate into
the kidney cortex and cause extensive interstitial lesions (Figs. 3
and 4A). By comparison, renal injury is not noted in similarly
manipulated C3H-11 mice; only a modest accumulation of cells
is noted under the renal capsule at 28 days post-Ix, and these cells
do not invade the kidney cortex (Fig. 4B). As we have previously
reported [12–15], infusion of uninfected TEC under the renal
capsule does not incite renal injury in MRL-Faslpr, MRL-11, or
C3H-11 mice (Fig. 4C). Furthermore, placing RANTES-TEC
under the renal capsule of MRL-Faslpr, MRL-11, or C3H-11
mice for 28 days does not foster the accumulation of leukocytes or
incite renal damage in the unmanipulated contralateral kidney
(data not shown). We have excluded the possibility that the renal
damage incited by RANTES-TEC in MRL-Faslpr kidney is a
result of retroviral transduction of the TEC. TEC transduced with
the TNF-a gene placed under the renal capsule of MRL-Faslpr
mice elicits only an accumulation of inflammatory cells which
remain localized in the subcapsular space, but do not infiltrate
into the cortex, similar to the response to infusion of uninfected
TEC (Fig. 4D). Taken together, these data indicate that expres-
sion of RANTES in the kidney of autoimmune MRL-Faslpr mice,
but not normal mice, specifically incites inflammatory renal
damage.
RANTES incites an accumulation of CD41 > CD81 >> DN T
cells, and few Mø in MRL-Faslpr kidneys
To identify the inflammatory cell phenotypes recruited by
RANTES in the MRL-Faslpr kidney, the accumulation of CD41,
CD81, or DN T cells (CD42, CD82, CD21/352B2201) and Mø
(F4/80) was evaluated in the incited lesion at 7 and 28 days
post-Ix. At seven days post-Ix, RANTES incited an accumulation
of predominantly Mø and CD41 T cells in the induced lesion
(Table 1). By 28 days post-Ix, the balance of infiltrating cells
recruited by RANTES had shifted to predominantly CD41 T
cells, lesser numbers of CD81 T cells and Mø, but few DN T cells
(Table 1 and Fig. 5). Furthermore, RANTES induced a promi-
nent accumulation of CD41 T cells in the interstitium and
surrounding glomeruli in MRL-Faslpr kidneys, that was absent in
normal kidneys (Fig. 6).
Since CSF-1 is up-regulated in MRL-Faslpr mice prior to renal
injury [3, 4], in a similar time frame as RANTES, we compared
the inflammatory T cell subsets recruited by CSF-1 and RANTES
using our gene transfer strategy at 7 and 28 days post-Ix. These
time points were selected to reflect the early and late events
incited by RANTES and CSF-1. At seven days post-Ix, CSF-1-
TEC induced a prominent accumulation of Mø, but unlike
RANTES, induced an equal accumulation of CD41, CD81, and
DN T cells (Table 1). By 28 days post-Ix, the difference in the
attraction of T cell subsets by RANTES and CSF-1 was even more
pronounced. RANTES elicited predominantly CD41 T cells and
fewer CD81 T cells, while DN T cells were notably absent. In
contrast, CSF-1 elicited equal numbers of CD41 and DN T cells,
and no CD81 cells (Table 1). It should be noted that we did not
detect CD21/351 cells in the CSF-1 induced kidney lesion, but by
comparison, CD21/351 cells were abundant in the normal spleen
control. Thus, RANTES and CSF-1 both initially attract Mø,
however, these cytokines foster distinct and complementary T cell
subsets in the MRL-Faslpr kidney.
Combining CSF-1-TEC and RANTES-TEC under the renal
capsule causes an additive increase in renal damage
Since expression of both CSF-1 and RANTES increases in the
kidneys of MRL-Faslpr mice prior to overt renal injury [3, 4], and
these cytokines recruit complementary inflammatory T cell sub-
sets, we investigated whether CSF-1 and RANTES interact to
accelerate renal damage. CSF-1-TEC and RANTES-TEC were
implanted together under the renal capsule of MRL-Faslpr mice
and evaluated for renal damage at 28 days post-Ix. The simulta-
neous expression of CSF-1 and RANTES in the MRL-Faslpr
kidney resulted in an additive increase in the size of cortical
lesions emanating from the subcapsular implant site, as compared
Fig. 3. RANTES incites progressive renal injury. The progression of
renal injury induced by RANTES-TEC in MRL-Faslpr, MRL-11 and
C3H-11 mice was determined at 7 (f), 14 (o), and 28 (u) days post-Ix.
Intrarenal lesions emanating from the subcapsular implant were scored
according to the depth of infiltration into the kidney; 0 5 none, 1 5 cortex,
2 5 inner cortex, 3 5 medulla. Values are expressed as the mean 6 SE;
N $ 3 mice per group. * P , 0.05.
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Fig. 4. RANTES incites renal injury in
autoimmune MRL-Faslpr, but not in C3H-11
mice with normal kidneys. RANTES-TEC
incite a massive accumulation of mononuclear
cells under the renal capsule (SC; subcapsule)
that actively infiltrated into the kidney cortex
(arrows) causing large interstitial lesions in
autoimmune MRL-Faslpr mice (A). By contrast,
RANTES-TEC placed under the renal capsule
of normal C3H-11 mice, induce a modest
accumulation of cells at 28 days post-Ix (B).
Uninfected TEC (C) or TNF-TEC (D) placed
under the renal capsule of MRL-Faslpr mice do
not incite a renal lesion (paraffin-embedded
tissue sections, hematoxylin and eosin stained;
magnification 3400).
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with kidneys implanted with RANTES-TEC or CSF-1-TEC alone
(Table 2). This implies that RANTES and CSF-1 independently
incite renal damage, but do not interact to synergistically enhance
tissue injury.
DISCUSSION
Increasing evidence suggests that RANTES is instrumental in
renal inflammation. In support of this concept, RANTES is
detected in several forms of renal injury. For example, RANTES
gene expression has been detected in human and rat renal
allograft rejection [29, 30], and an induced form of anti-GBM
nephritis in the rat [23, 31]. This study investigated the importance
of RANTES in autoimmune kidney destruction. We now report
that RANTES is expressed in the kidney cortices of autoimmune
MRL-Faslpr mice prior to renal injury and increases with the
severity of nephritis. Furthermore, a connection between
RANTES expression in the kidney and renal damage using an ex
vivo gene transfer strategy is established. RANTES secreting TEC
infused under the renal capsule of pre-diseased MRL-Faslpr mice
elicit an intrarenal lesion extending from the implanted subcap-
sular site into the cortex, which is absent in similarly manipulated
MRL-11 or C3H-11 mice with normal kidneys. Furthermore,
RANTES promotes the influx and propagation of Mø and specific
T cell subsets, CD41 . CD81 . DN T cells, into the MRL-Faslpr
kidney. Together, these data establish that RANTES expression
in the kidney of autoimmune MRL-Faslpr mice promotes the
recruitment and accumulation of Mø and CD41 and CD81 T
cells, and in turn, incites renal damage.
RANTES expression in the kidney requires a suitable genetic
background (MRL) and a contributing molecular factor (Faslpr
mutation) to incite renal pathology. This finding parallels our
previous observation that CSF-1, up-regulated in the MRL-Faslpr
kidney, incites renal damage in mice with the Faslpr mutation, but
not in normal strains [12]. It is important to appreciate that the
capacity of RANTES and CSF-1 to elicit renal pathology is
specific and not related to retroviral genes. Using the same gene
transfer system, IL-6 and TNF-a did not elicit renal pathology [14,
15]. Thus, renal pathology in response to RANTES and CSF-1
delivery into the kidney is a specific consequence of the properties
of these molecules to recruit and activate autoreactive inflamma-
tory cells. We speculate that RANTES fails to elicit renal injury in
normal C3H-11 mice since autoreactive T cells are not available
to target the kidney. It should be noted that MRL-11 mice are
pre-disposed to autoimmune renal disease, which is manifested in
the second year of life [2]. Since autoimmune MRL background
genes are required for renal injury, it is not surprising that in our
study, renal damage was initiated in only a small percentage of
MRL-11 kidneys implanted with RANTES-TEC. This would
suggest that in the presence of RANTES, other molecules re-
quired to incite renal damage may be available, at least in some
MRL-11 mice, well in advance of renal injury.
To evaluate the early and more distal impact of RANTES
expression on kidney pathology, mice were examined at 7 to 28
days following implantation of cytokine-TEC. It should be noted
that renal pathology in MRL-Faslpr mice examined following
delivery of RANTES for 28 days is minimal. We previously
established that a small increase in Mø and the beginning of
perivascular infiltration of T cells can be detected [12]. Our prior
studies indicate that CSF-1-TEC deliver high sustained levels of
CSF-1 and remain localized in the subcapsular implant site for 28
days post-Ix [12]. Since in our system, the implanted TEC delivers
RANTES locally into a single kidney, renal pathology is restricted
to the area proximal to the implant site and survival is not
compromised. Even in studies in which TEC deliver GM-CSF into
the kidney for three months, although the lesion continued to
expand, there was insufficient amount of renal damage to be fatal
[12]. This is not surprising and suggests that a more diffuse
Table 1. RANTES and CSF-1 promote the accumulation of different T
cell subsets in the kidney MRL-Faslpr mice
Phenotype
Cell accumulation within lesion post-Ix
7 days 28 days
RANTES CSF-1 RANTES CSF-1
Macrophage
(F4/80)
136 6 14 210 6 30 253 6 9 175 6 38
(53.1%) (68.2%) (11.5%) (10.5%)
T cells
CD41 70 6 16a 33 6 5 1157 6 24a 700 6 154
(27.3%) (10.7%) (52.4%) (42.0%)
CD81 48 6 9a 29 6 4 631 6 13a 55 6 13
(18.8%) (9.4%) (28.5%) (3.3%)
DNb 2 6 1a 36 6 7 168 6 3a 735 6 162
(0.8%) (11.7%) (7.6%) (44.1%)
Recipients were MRL-Faslpr mice, 8 weeks of age; N 5 3; 1 3 106 TEC
implanted. Abbreviations are: CSF-1, colony stimulating factor-1; Ix,
implantation.
Cell phenotypes in intrarenal lesions are reported as the mean 6 SE of
F4/80, B220, CD4 or CD8 positive cells in 6 fields of 340.
a P , 0.05, as compared to CSF-1
b DN 5 CD42, CD82, B2201
Fig. 4. Continued.
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delivery of these cytokines is required to cause the loss of renal
function.
The interaction of the Faslpr mutation and the MRL back-
ground results in a rapid and fatal spontaneous renal injury
characterized by the infiltration of Mø and multiple T cell subsets
into the kidney [2]. Fas mediates apoptosis of autoreactive T cells
in the periphery, and mutation of this gene results in the
accumulation of a unique subset of DN T cells [1]. These DN T
cells accumulate in equal numbers with CD41 T cells within
perivascular and interstitial lesions, while CD81 T cells are fewer
in number [32]. Thus, it is notable that our gene transfer study
demonstrates that RANTES recruits substantial numbers of
CD41 and CD81 T cells into the MRL-Faslpr kidney. This
suggests that another molecule(s) present in the MRL-Faslpr
kidney is responsible for recruiting and fostering the accumulation
of DN T cells.
We have previously documented that the Mø growth factor
CSF-1 is expressed in the MRL-Faslpr kidney prior to renal injury,
beginning at four weeks of age, in glomeruli and TEC, and
expression increases with disease severity [3, 4]. Thus, CSF-1 and
RANTES are up-regulated in the MRL-Faslpr kidney at a similar
time point. Therefore, we compared the individual contributions
Fig. 5. RANTES incites an accumulation of CD41 > CD81 > DN T cells in MRL-Faslpr kidneys. RANTES-TEC placed under the renal capsule of
MRL-Faslpr mice, induce a predominant accumulation of CD41 cells (dark staining) (a), and CD81 cells (b) within the interstitial lesion at 28 days
post-implantation (Ix). In contrast to CD41 and CD81 cells, Mø accumulate along the periphery of the lesion (c), and few DN T cells are observed
within the lesion (d) (frozen tissue sections; magnification 31000 for a and b; 3800 for c and d).
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of CSF-1 and RANTES in the recruitment of inflammatory cells,
and assessed their combined impact on renal pathology in MRL-
Faslpr mice. While both RANTES and CSF-1 promote an initial
influx of Mø, they differ significantly in their attraction and
propagation of T cell subsets: CSF-1 promotes the accumulation
of CD41 and DN T cells, while RANTES promotes the accumu-
lation of CD41 and CD81 T cells in the kidney of MRL-Faslpr
mice. Since renal disease consists of CD41, CD81, DN T cells in
MRL-Faslpr mice, it is likely that both RANTES and CSF-1
contribute to the progression of autoimmune renal injury.
Since CSF-1 and RANTES recruit distinct and complementary
T cell subsets into the MRL-Faslpr kidney, we evaluated the
impact of dual delivery of CSF-1 and RANTES on renal pathol-
ogy in MRL-Faslpr mice. We would predict that the simultaneous
recruitment of Mø, CD41 and CD81 T cells by RANTES, and
Mø, CD41 and DN T cells by CSF-1, would create an explosive
environment for inflammatory renal injury. However, we were
surprised to determine that expression of both CSF-1 and
RANTES in the MRL-Faslpr kidney resulted in an additive, not
synergistic, increase of renal damage. Thus, unlike TNF-a, which
we have previously shown to interact with CSF-1 to potently
increase renal injury [14], RANTES mediates renal damage
independently of CSF-1. Therefore, we conclude that CSF-1 and
RANTES recruit distinct T cell subsets, which together constitute
the total T cell populations that accumulate in spontaneous renal
lesions of MRL-Faslpr mice, but these cytokines do not interact to
enhance the infiltration of leukocytes into the kidney.
The chemoattraction of inflammatory cells into a site of tissue
damage such as the kidney is mediated by a cascade of molecular
events, including endothelial cell activation, the expression of
adhesion molecules, leukocyte-endothelial adhesive interactions,
diapedesis and the migration of leukocytes beyond vascular
barriers [33, 34]. There are several possible mechanisms whereby
RANTES may facilitate T cell and Mø accumulation in the
MRL-Faslpr kidney and incite renal damage, including: (1) direct
chemoattraction [18], and/or (2) cellular activation [35, 36], and/or
(3) cytokine induction. The probability of each mechanism is
discussed below.
The recruitment of leukocytes from the circulation into the
kidney via chemoattraction requires the maintenance of a stable
chemokine gradient [33]. In addition, the leukocytes must over-
come a forceful hydrostatic barrier. RANTES is expressed by
renal mesangial and tubular epithelial cells (TEC), and by infil-
trating T lymphocytes [21–24]. Furthermore, RANTES binds to
proteoglycans on the surface of capillary endothelial cells, and
thus provides a strong, constant chemokine gradient whereby
leukocytes are attracted [37]. Following the recruitment of leuko-
cytes, RANTES strengthens adhesive interactions between endo-
thelial cells and T cells/Mø by up-regulating ICAM-1, ICAM-3,
CD43, CD44 and CD11b/c [38, 39], and by enhancing adhesion of
T cells to the extracellular matrix [25]. Thus, RANTES expression
in the MRL-Faslpr kidney both initiates migration of leukocytes to
this site and fosters leukocyte accumulation by enhancing the
adhesion of the recruited cells.
In addition to directing chemotaxis of leukocytes, RANTES is a
potent cellular activator of both T cells and Mø, and can induce
cytokine production [18]. Activation of Mø by RANTES results in
the release of a large number of monokines such as CSF-1,
TNF-a, IL-1b, and IL-6 in the kidney [40]. It should be noted that
each of these molecules are detectable in the MRL-Faslpr kidney
Fig. 6. RANTES incites an interstitial and periglomerular accumulation
of CD41 T cells in MRL-Faslpr kidneys. RANTES-TEC placed under the
renal capsule of MRL-Faslpr mice, induce a prominent accumulation of
CD41 T cells (dark staining; arrows) outside the induced lesion, surround-
ing glomeruli (A), and within the interstitium (B) at 28 days post-
implantation (Ix) (frozen tissue sections; magnification A 31200 and B
3400).
Table 2. Introduction of CSF-1 and RANTES into the kidney
additively increases renal injury in MRL-Faslpr mice
Strain N TEC Ixa
Intrarenal
lesionb
MRL-Faslpr 4 RANTES 1 CSF-1 1.1 6 0.9
3 RANTES 1 Uninf. 0.8 6 0.3
3 CSF-1 1 Uninf. 0.3 6 0.2
3 Uninf. 0 6 0
Values represent mean 6 SE.
a RANTES 1 CSF-1: 1 3 106 TEC each; RANTES or CSF-1 alone: 1 3
106 1 1 3 106 uninfected TEC to equalize N of cells. Mice were sacrificed
at 28 days post-implantation (Ix) and the lesion extending from the
implant site was quantified by b Grade of infiltration: 0 5 none, 1 5 outer
cortex, 2 5 inner cortex, 3 5 outer medulla
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undergoing autoimmune destruction [3–8]. In addition, the acti-
vation of T cells by RANTES results in an autocrine up-regulation
of RANTES [24], further compounding this inflammatory re-
sponse. The initiation of a cytokine cascade, as a result of
RANTES activation of Mø and T cells, leads to the additional
recruitment of leukocytes and amplification of tissue damage.
Thus, we propose that expression of RANTES in the MRL-Faslpr
kidney prior to the onset of disease directs the extravascular
migration of leukocytes and primes these cells to initiate tissue
damage. Furthermore, the unleashing of this inflammatory reac-
tion results in the continual increase in RANTES in the MRL-
Faslpr kidney, and is in turn responsible for driving kidney
destruction.
The cause of RANTES up-regulation in the MRL-Faslpr kidney
is unknown. Multiple cytokine abnormalities in MRL-Faslpr mice
may be responsible for an increase in RANTES in the kidney. For
example, CSF-1, TNF-a, TGF-b and IL-1b are up-regulated in
the kidney, and increases with progressive renal damage [3–8].
Since both TNF-a and IL-1b induce secretion of RANTES by
mesangial cells, it is possible that dysregulation of TNF-a and
IL-1b in the MRL-Faslpr kidney promotes the production of
RANTES [20, 41]. Conversely, RANTES expression may precede
CSF-1, TNF-a, and IL-1b, since activation of Mø by RANTES
induces the release of these pro-inflammatory cytokines [40].
Thus, it is unclear whether RANTES is the primary molecular
defect, or whether another cytokine is responsible for its induc-
tion. Taken together, the simultaneous dysregulation of
RANTES, CSF-1, TNF-a, and IL-1b in the MRL-Faslpr kidney
creates a volatile inflammatory environment; however, it is un-
clear which molecule(s) initiates this cascade.
Even though whether or not RANTES is induced by a cyto-
kine(s) in the MRL-Faslpr kidney is yet unknown, it is clear that
MRL genes which regulate Mø and cytokine abnormalities pro-
mote autoimmune kidney destruction. For example, Mø of MRL
mice (11, Faslpr) hyperrespond to CSF-1 and TNF-a, resulting in
rapid proliferation and accumulation of Mø in the kidney, and
renal injury [13, 14]. We propose that the simultaneous expression
RANTES, CSF-1, TNF-a, and IL-1b, and the unique responses of
MRL-Faslpr Mø to CSF-1 and TNF-a, drive the fulminant renal
injury characteristic of the MRL-Faslpr strain.
In conclusion, we report that RANTES is expressed in the
kidney of MRL-Faslpr mice prior to onset of disease and increases
with progressive nephritis. Using a retroviral gene transfer strat-
egy, we establish that RANTES elicits autoimmune renal damage.
Together this suggests that intrarenal RANTES in MRL-Faslpr
mice is associated with autoimmune renal disease. In addition, we
report that RANTES is responsible for the accumulation of CD41
and CD81, but few DN T cells in the MRL-Faslpr kidney. Since we
have established that CD41 T cells are required to incite renal
injury in MRL-Faslpr mice (manuscript in preparation), we predict
that strategies that mask the expression of RANTES would be
therapeutic and obviate autoimmune renal injury. Further studies
with mouse Ab or antagonist molecules that would block intrare-
nal RANTES would be informative, however, these reagents are
presently unavailable.
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APPENDIX
Abbreviations used in this article are: CSF-1, colony stimulating
factor-1; DN, double negative; IL, interleukin; IX, implantation;
Mø, macrophage; PBS, phosphate buffered saline; RANTES,
Regulated upon Activation, Normal T cell Expressed and Se-
creted; TEC, tubular epithelial cells; TGFb, transforming growth
factor-b; TNF-a, tumor necrosis factor-a.
REFERENCES
1. SINGER GG, CARRERA AC, MARSHAK-ROTHSTEN A, MARTINEZ-A C,
ABBAS AK: Apoptosis, Fas and systemic autoimmunity: The MRL-
lpr/lpr model. Curr Opin Immunol 6:913–920, 1994
2. KELLEY VE, ROTHS JB: Interaction of mutant lpr gene with back-
ground strain influences renal disease Clin Immunol Immunopathol
37:220–229, 1985
3. YUI MA, BRISSETTE WH, BRENNAN DC, WUTHRICH RP, KELLEY VE:
Increased macrophage colony-stimulating factor in neonatal and adult
autoimmune MRL-lpr mice. Am J Pathol 139:255–261, 1991
4. BLOOM RD, FLORQUIN S, SINGER GG, BRENNAN DC, KELLEY VR:
Colony stimulating factor-1 in the induction of lupus nephritis. Kidney
Int 43:1000–1009, 1993
5. YOKOYAMA H, KREFT B, KELLEY VR: Biphasic increase in circulating
and renal TNF-a in MRL-lpr mice with differing regulatory mecha-
nisms. Kidney Int 47:122–130, 1995
6. BOSWELL JM, YUI MA, BURT DW, KELLEY VE: Increased tumor
necrosis factor and IL-1b expression in the kidneys of mice with lupus
nephritis. J Immunol 141:3050–3054, 1988
7. TANG B, MATSUDA T, KISHIMOTO T: Age-associated increase in
interleukin-6 in MRL/lpr mice. Int Immunol 3:273–278, 1991
8. KREFT B, YOKOYAMA H, NAITO T, KELLEY VR: Dysregulated trans-
forming growth factor-beta in neonatal and adult autoimmune MRL-
lpr mice. J Autoimmun 9:463–472, 1996
9. BOSCH R, WOOLF AS, FINE LG: Gene transfer into mammalian
kidney: Direct retrovirus-transduction of regenerating tubular epithe-
lial cells. Exp Nephrol 1:49–54, 1993
10. ISAKA Y, FUJIWARA Y, IMAI E: Glomerulosclerosis induced by in vivo
transfection of transforming growth factor-b or platelet-derived
growth factor gene into the rat kidney. J Clin Invest 92:2597–2601,
1993
11. KITAMURA M, TAYLER S, FINE LG: Gene transfer into the rat renal
glomerulus via a mesangial cell vector: Site-specific delivery, in situ
amplification, and sustained expression of an exogenous gene in vivo.
J Clin Invest 94:497–505, 1994
12. NAITO T, YOKOYAMA H, MOORE KJ, DRANOFF G, MULLIGAN RC,
KELLEY VR: Macrophage growth factors introduced into the kidney
initiate renal injury. Molec Med 2:297–312, 1995
13. MOORE KJ, NAITO T, MARTIN C, KELLEY VR: Enhanced response of
macrophages to CSF-1 in autoimmune mice. A gene transfer strategy.
J Immunol 157:433–440, 1996
14. MOORE KJ, YEH K, NAITO T, KELLEY VR: TNF-a enhances colony-
stimulating factor-1-induced macrophage accumulation in autoim-
mune renal disease. J Immunol 157:427–432, 1996
15. NAITO T, YOKOHAMA H, MOORE KJ, DRANOFF G, MULLIGAN RC,
KELLEY VR: A gene transfer approach establishes IL-6 neither
promotes nor suppresses renal injury. Am J Physiol 271:F603–F609,
1996
16. BRENNAN DC, JEVNIKAR AJ, BLOOM RD, BRISSETTE WH, SINGER GG,
RUBIN-KELLEY VE: Cultured mesangial cells from autoimmune
MRL-lpr mice have decreased secreted and surface M-CSF. (abstract)
Kidney Int 42:279, 1992
17. NAITO T, GRIFFITHS RC, COFFMAN TM, KELLEY VR: Transplant
approach establishes that kidneys are responsible for serum CSF-1 but
require a stimulus in MRL-lpr mice. Kidney Int 49:67–74, 1996
18. TAUB DD, OPPENHEIM JJ: Chemokines, inflammation and the im-
mune system. Ther Immunol 1:229–246, 1994
Moore et al: RANTES accelerates autoimmune renal damage1640
19. SCHALL TJ, BACON K, TOY KJ, GOEDDEL DV: Selective attraction of
monocytes and T lymphocytes of the memory phenotype by the
chemokine RANTES. Nature 347:669–671, 1990
20. WANG JM, MCVICAR DW, OPPENHEIM JJ, KELVIN DJ: Identification
of RANTES receptors on human monocytes: Competition for binding
and desensitization by homologous chemotactic cytokines. J Exp Med
177:699–705, 1993
21. ROBSON RL, WESTWICK J, BROWN Z: Differential regulation of
RANTES in response to IL-1a and TNF-a in human mesangial cells.
(abstract) J Am Soc Nephrol
22. HEEGER P, WOLF G, MEYERS C: Isolation and characterization of
cDNA from renal tubular epithelium encoding murine RANTES.
Kidney Int 41:220–225, 1992
23. THAISS F, HELMCHEN U, ZAHNER G, HABERSTROH U, RADOUNIKLI N,
SCHOEPPE W, STAHL RA: muRANTES mRNA expression in glomer-
uli isolated from rats with autologous nephrotoxic serum nephritis.
(abstract) J Am Soc Nephrol 4:638, 1993
24. CONLON K, LLOYD A, CHATTOPADHYAY U, LUKACS N, KUNKEL S,
SCHALL T, TAUB D, MORIMOTO C, OSBORNE J, OPPENHEIM J, YOUNG
H, KELVIN D, ORTALDO J: CD81 and CD45RA1 human peripheral
blood lymphocytes are potent sources of macrophage inflammatory
protein-1a, interleukin-8 and RANTES. (abstract) Eur J Immunol
25:751, 1995
25. GILAT D, HERSHKOVIZ R, MEKORI YA, VIODAVSKY L, LIDER O:
Regulation of adhesion of CD41 T lymphocytes to intact or hepari-
nase-treated subendothelial matrix by diffusible or anchored
RANTES or MIP-1a. J Immunol 153:4899–4906, 1994
26. WUTHRICH RP, GLIMCHER LH, KELLEY VE: MHC class II, antigen
presentation and tumor necrosis factor in renal tubular epithelial cells.
Kidney Int 37:783–792, 1990
27. DANOS O, MULLIGAN RC: Safe and efficient generation of recombi-
nant retroviruses with amphotropic and ecotropic host ranges. Proc
Natl Acad Sci USA 85:6460–6464, 1988
28. CHOMCZYNSKI P, SACCHI N: Single-step method of RNA isolation by
acid guanidium thiocyanate-phenol-chloroform extraction. Anal Bio-
chem 162:156–159, 1987
29. PATTISON J, NELSON PJ, HUIE P, LEUTTICHAU I, FARSHID G, SIBLEY
RK, KRENSKY AM: RANTES chemokine expression in cell-mediated
transplant rejection of the kidney. Lancet 343:209–211, 1994
30. NADEAU KC, AZUMA H, TILNEY NL: Sequential cytokine dynamics in
chronic rejection of rat renal allografts: Roles for cytokines RANTES
and MCP-1. Proc Natl Acad Sci USA 92:8729–8733, 1996
31. TANG WW, YIN S, WITTWER AJ, QI M: Chemokine gene expression in
anti-glomerular basement membrane antibody glomerulonephritis.
Am J Physiol 269:F323–F330, 1995
32. DAVIGNON JL, BUDD RC, CEREDIG R, PIGUET PF, MACDONALD HR,
CEROTTINI JC, VASSALI P, IZUI S: Functional analysis of T cell subsets
from mice bearing the lpr gene. J Immunol 135:2423–2428, 1985
33. SPRINGER TA: Traffic signals for lymphocyte recirculation and leuko-
cyte emigration: The multi-step paradigm. Cell 76:301–314, 1994
34. BUTCHER EC: Leukocyte-endothelial cell recognition: Three (or
more) steps to specificity-diversity. Cell 67:1033–1036, 1991
35. TAUB DD, ORTALDO JR, TURCOVSKI-CORRALES SM, KEY ML, LONGO
DL, MURPHY WJ: b-Chemokine costimulation, lymphocyte cytolysis,
proliferation and lymphokine production. J Leuk Biol 59:81–89, 1996
36. TAUB DD, TURCOVSKI-CORRALES SM, KEY ML, LONGO DL, MURPHY
WJ: Chemokines and T lymphocyte activation: I. Beta chemokines
costimulate human T lymphocyte activation in vitro. J Immunol
156:2095–2103, 1996
37. TANAKA Y, ADAMS DH, SHAW S: Proteoglycans on endothelial cells
present adhesion-inducing cytokines to leukocytes. Immunol Today
14:111–115, 1993
38. DEL POZO MA, SANCHEZ-MATEOS P, NIETO M, SANCHEZ-MADRID F:
Chemokines regulate cellular polarization and adhesion receptor
redistribution during lymphocyte interaction with endothelium and
extracellular matrix. Involvement of cAMP signalling pathway. J Cell
Biol 131:495–508, 1995
39. VADDI K, NEWTON RC: Regulation of monocyte integrin expression
by beta-family chemokines. J Immunol 153:4721–4732, 1994
40. NIKOLIC-PATERSON DJ, LAN HY, HILL PA, ATKINS RC: Macrophages
in renal injury. Kidney Int 45(Suppl 45):S79–S82, 1994
41. WOLF G, ABERLE S, THAISS F, NELSON PJ, KRENSKY AM, NEILSON
EG, STAHL RA: TNF-a induces expression of the chemoattractant
cytokine RANTES in cultured mouse mesangial cells. Kidney Int
44:795–804, 1993
Moore et al: RANTES accelerates autoimmune renal damage 1641
